HAVCR2 and cancer: They further identified a noncanonical mesenchymal–epithelial transition (MET) activity of etoposide, which suppresses the EMT/β-catenin/STT3/PD-L1, leading to PD-L1 downregulation and sensitization of cancer cells to anti-Tim-3 therapy.